

Comparison of six irradiation techniques for delivering hypofractionated whole-breast radiotherapy with a simultaneous integrated boost after breast-conserving surgery

J. Zhang^{1#}, S.G. Wu^{2#}, J.Y. Sun¹, F.Y. Li¹, X.X. Guan¹, Z.Y. He^{1*}

¹Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, People's Republic of China

²Department of Radiation Oncology, Xiamen Cancer Hospital, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China

ABSTRACT

Background: To compare the following techniques for hypofractionated whole-breast irradiation (WBI) with simultaneous integrated boost (SIB) after breast-conserving surgery (BCS): three-dimensional conformal radiation therapy plus electron boost (3DCRT-EB), intensity-modulated radiation therapy (IMRT) plus EB (IMRT-EB), field-in-field IMRT plus EB (FIF-IMRT-EB), FIF-IMRT plus IMRT boost (FIF-IMRT-IB), IMRT plus IMRT boost (IMRT-IB), and volumetric-modulated arc therapy (VMAT) plus VMAT boost (VMAT-VB). **Materials and Methods:** Twenty patients with left breast cancer were enrolled. The prescribed dose was 40.05 Gy in 15 fractions to the whole breast and an SIB to the tumor bed of 3.2 Gy/fraction (total, 48 Gy). Target-volume coverage, dose-conformity index, homogeneity index (HI), doses to organs at risk (OAR), and costs were compared. **Results:** FIF-IMRT-EB performed the best, while FIF-IMRT-IB, IMRT-IB, and VMAT-VB performed the worst. The mean dose to the planning target volume for breast evaluation (PTV Eval-breast) was significantly lower for IMRT-EB and FIF-IMRT-EB than for the other plans. For both PTV Eval-breast and PTV Eval-boost, VMAT-VB had the lowest target-volume coverage for 95% of the prescription dose and the highest target-volume coverage for >105% of the prescription dose. Among the six plans, VMAT-VB had the best HI for PTV Eval-boost and the highest doses to all OAR, except the coronary artery. Plans with EBs had lower mean doses for the contralateral lung and contralateral breast than plans with IMRT boosts. FIF-IMRT-EB had a low cost; plans with IMRT boosts had the highest costs. **Conclusion:** FIF-IMRT-EB may be the most suitable irradiation technique for hypofractionated WBI with SIB after BCS.

Keywords: Breast cancer, breast-conserving surgery, hypofractionated whole-breast radiotherapy, radiotherapy, simultaneous integrated boost.

► Original article

*Corresponding authors:

Dr. Z.Y. He,

Fax: + 86 20 87343392

E-mail: hezhy@sysucc.org.cn

Revised: July 2017

Accepted: August 2017

Int. J. Radiat. Res., July 2018;
16(3): 269-278

DOI: 10.18869/acadpub.ijrr.16.3.269

These authors contributed equally to this work.

INTRODUCTION

Breast-conserving surgery (BCS) plus postoperative radiotherapy has been shown to yield equivalent outcomes as mastectomy, with better cosmetic results ⁽¹⁾. However, some patients choose to directly have a mastectomy, and some may not receive

radiotherapy for 5–7 weeks after BCS due to the limitations of conventional breast irradiation ^(2, 3). Accelerated hypofractionated irradiation can shorten the duration of radiotherapy to approximately 3 weeks. Randomized controlled trials have demonstrated similar local control rates, overall survival, and cosmetic outcomes between accelerated hypofractionated

irradiation and conventional fractionated irradiation⁽⁴⁻⁷⁾. However, the use of a tumor bed boost after whole-breast irradiation (WBI) has been shown to significantly improve outcomes (range, 0–74.5%) as compared to WBI without a tumor bed boost⁽⁸⁾. A randomized study has reported that among patients who received WBI with conventional fractionation, a tumor bed boost was associated with better local control rates than those in the non-boost group⁽⁹⁾. Currently, there is limited evidence from randomized trials regarding the efficacy and tolerability of hypofractionated WBI with a simultaneous integrated tumor bed boost for breast cancer. Several randomized trials to compare the benefits of simultaneous integrated boost (SIB) with hypofractionated and conventional fractionated WBI are ongoing⁽¹⁰⁻¹³⁾.

A better SIB technique should be systematically developed to avoid adverse *cosmetic outcomes after* tumor bed boost⁽¹⁴⁾. Recently, several prospective studies have assessed modern radiotherapy techniques, including intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT)⁽¹⁵⁻¹⁷⁾. However, there are no well-defined standards for using SIB as part of hypofractionated WBI after BCS. In this study, we compared six radiotherapy techniques in terms of the target volume coverage, dose conformity and homogeneity indexes, doses to organs at risk (OAR), and cost in order to determine the optimal technique for accelerated hypofractionated WBI with SIB.

MATERIALS AND METHODS

Patients

The study involved 20 patients with early-stage cancer of the left breast who underwent radiotherapy after BCS at the Sun Yat-Sen University Cancer Center (SYSUCC) between August 2014 and December 2014. The inclusion criteria were as follows: (1) female patient with a single-lesion cancer of the left breast after BCS and negative surgical margins;

(2) negative axillary lymph node or sentinel lymph node; (3) T1–2N0M0 stage according to the American Joint Committee on Cancer staging system; (4) hormone receptor status and human epidermal growth factor receptor 2 (Her 2) status available; and (5) endocrine therapy and/or adjuvant chemotherapy performed according to treatment guidelines. The ethics committee of SYSUCC approved this study. Table 1 shows the characteristics of the patients.

Table 1. Clinicopathological characteristics of the 20 study patients

Characteristic	Value
Age (yr)	
Median	43
Mean (SD) (years)	42.5±10.4
Range	36-56
Menopausal status (n)	
Premenopausal	22
Postmenopausal	6
Tumor stage (n)	
T1	16
T2	13
Tumor location (n)	
UIQ	4
UOQ	12
LIQ	2
LOQ	2
Pathological type (n)	
Invasive ductal carcinoma	19
Mucinous adenocarcinoma	1
ER/PR status (n)	
Negative	6
Positive	14
Her-2 status (n)	
Negative	18
Positive	2
Sentinel nodes sampled (n)	
No	12
Yes	8
Axillary lymph node dissection (n)	
No	8
Yes	12

ER, estrogen receptor; Her-2, human epidermal growth factor receptor 2; LIQ, lower inner quadrant; LOQ, lower outer quadrant; PR, progesterone receptor; SD, standard deviation; UIQ, upper inner quadrant; UOQ, upper outer quadrant.




Figure 1. Delineation of the target volume and organs at risk.

Target volumes and OAR

The clinical target volume (CTV) was delineated in accordance with the guidelines of International Commission on Radiation Units Report 83⁽¹⁸⁾. The delineation of lumpectomy, planning target volume (PTV) of the breast, PTV for evaluation (PTV Eval-breast), and OAR was primarily based on our previous report (figure

1)⁽¹⁹⁾. We expanded the CTV isotropically with a 0.7-cm margin in all directions, except toward the skin surface, to generate the PTV. The coronary artery was identified as the area of left front one-fourth heart 1 cm subsurface⁽²⁰⁾. The target volumes and the volumes of the OAR are shown in table 2.

Table 2. Target volume and volumes of organs at risk in the 20 study patients

	Volume		
	Mean \pm SD (cm ³)	Median (cm ³)	Range (cm ³)
PTV-Whole breast	115.2 \pm 474.9	472.3	645.2-276.2
PTV-Boost	13.9 \pm 60.2	58.6	98.2-47.2
Ipsilateral lung	182.0 \pm 1088.0	1057.6	1599.8-812.8
Contralateral lung	262.7 \pm 1188.5	1195.3	1783.1-654.2
Heart	65.8 \pm 534.5	557.3	643.3-374.1
Contralateral breast	113.5 \pm 469.5	456.0	653.6-298.3
Coronary artery	3.4 \pm 60.1	60.3	64.8-52.8
Thyroid	3.7 \pm 10.2	10.3	19.8-5.6

PTV, planning target volume; SD, standard deviation

Radiotherapy plans

Six radiotherapy plans were generated for each patient, by using the Eclipse treatment planning system (version 11.0.1, Varian Medical Systems, Los Angeles, CA, USA). The prescribed dose was 40.05 Gy delivered in 15 fractions to the whole breast (2.67 Gy/fraction) and an SIB to the tumor bed of 3.2 Gy/fraction (total SIB dose, 48 Gy). The dose-volume criteria were

assessed according to the Radiation Therapy Oncology Group 1005 protocol⁽¹³⁾.

1. Three-dimensional conformal radiation therapy plus an electron boost (3DCRT-EB):

A pair of opposed tangential fields were used to irradiate the whole breast. By applying a wedge plate or adjusting the collimator angle, the tangential field of the lung was kept close to the

minimum, the healthy breast was completely avoided, and the dose distribution was made more even. Single-field EB plans were used to cover the PTV for evaluation of the boost irradiation (PTV Eval-boost). EBs were planned with energies of 6–15 MeV, depending on the depth of the PTV Eval-boost, to ensure that the PTV Eval-boost covered the 95% isodose line.

2. Field-in-field IMRT plus an EB (FIF-IMRT-EB): In brief, the contribution of parallel opposed tangential photon beams without wedges and multiple subfields was used to achieve the desired homogeneity of the PTV Eval-breast. The dose distributions were first calculated and assessed using open beams. Additional subfields and a lung block were used to smooth out the hot areas and the lung shape to increase the homogeneity and reduce the dose to the lung. Subfields within 5 MU were removed. A single-field EB was used for each PTV Eval-boost.

3. IMRT plus an EB (IMRT-EB): A two-field opposed IMRT plan was used for WBI. The angle of the radiation field was consistent with that of the 3DCRT plans, and inverse optimization was applied. Single-field EB plans were used for each PTV Eval-boost.

4. IMRT plus an IMRT boost (IMRT-IB): A two-field opposed IMRT plan was used for WBI. In addition, five fields with opposed tangential directions were generated to deliver a highly homogeneous dose to the PTV Eval-boost by using a “step and shoot” IMRT plan. Two adjacent beams in the same direction were separated by 20° to 30°. The maximum number of segments was 50.

5. FIF-IMRT plus an IMRT boost (FIF-IMRT-IB): The FIF-IMRT plan was designed using the method described for FIF-IMRT-EB. The IMRT boost plan was designed using the method described for IMRT-IB.

6. VMAT plus a VMAT boost (VMAT-VB): Two

180° arcs were used for each VMAT plan. The first arc started from the body midline. The starting angle was kept away from the breast, and the ending angle was 180° plus the starting angle. The second arc had exactly opposite starting and ending angles relative to the first arc. The collimator angle was adjusted on the basis of the individual target size. The PTV Eval-breast and PTV Eval-boost plans were optimized simultaneously.

Conformity index and homogeneity index

The conformity index (CI) and homogeneity index (HI) were calculated using the following formulae:

$CI = V_{95\%}/PTV$, where $V_{95\%}$ is the total volume receiving 95% of the prescribed dose (PD).

$HI = (D_{2\%} - D_{98\%})/D_{50\%}$, where $D_{2\%}$, $D_{98\%}$, and $D_{50\%}$ are the doses received by 2%, 98%, and 50% of the PTV.

The closer the HI and CI are to 1, the better is the plan ⁽²¹⁾.

Cost-benefit analysis

Our cost-benefit analysis included fees for initial consultation, computed tomography simulation, treatment planning, dosimetry calculation, quality assurance, and cost of radiotherapy. Because our study yielded multiparametric results, we implemented a quantitative scoring method to guide our evaluation and decisions regarding which was the superior technique. Under this method, 7 points were awarded to a plan if its performance for a given parameter was significantly better than that of all the other plans. When conducting pairwise comparisons of each parameter, points were subtracted from a plan's score if more than one plan performed significantly better than the rest of the plans, and the lowest value was taken from equivalent values. For example, if 3DCRT and IMRT-EB both performed significantly better than the other four plans, then the score for each of these two plans was 6. Otherwise, the score decreased to 1 gradually. The most cost-effective technique was the one that had the highest score on the cost-benefit analysis.

Statistical analysis

Data were analyzed using SPSS software (release 17.0, SPSS Inc., Chicago, IL, USA). We performed one-way analysis of variance to evaluate differences among the dosimetric parameters of the six radiotherapy techniques. All tests were two-sided, and $p < 0.05$ was considered to indicate significant differences.

RESULTS

Target-volume coverage

Table 3 and figure 2 show the dosimetric parameters for target-volume coverage for the six plans. The dosimetric parameters for PTV Eval-breast and the CI and HI were significantly better for the VMAT-VB plan than for the other plans ($p < 0.05$). The CI of 3DCRT was significantly worse than that of the other plans ($p = 4.49$). There were no significant differences in CI and HI among the four IMRT plans ($p > 0.05$).

The mean dose (Dmean) of the PTV Eval-breast was significantly lower in the IMRT-EB and FIF-IMRT-EB plans than in the other plans ($p < 0.05$). VMAT-VB had the lowest $V_{95\%}$ value and the highest $V_{105\%}$ value among all the plans. The $V_{95\%}$ values of the remaining five plans did not significantly differ from each other ($p > 0.05$). The $V_{105\%}$ value of FIF-IMRT-EB was significantly lower than those of the other plans ($p < 0.05$).

In the case of the PTV Eval-boost, the CIs of IMRT-EB, FIF-IMRT-EB, and VMAT-VB were significantly superior to those of the other plans ($p < 0.05$). VMAT-VB had the best HI of the six plans ($p < 0.05$). The Dmean of 3DCRT and VMAT-VB were greater than those of the other plans, while that of FIF-IMRT-EB was the lowest. VMAT-VB had the lowest $V_{95\%}$ and the highest $V_{105\%}$ among the six plans. The $V_{105\%}$ of IMRT-EB was significantly higher than that of FIF-IMRT-EB, but there were no significant differences in $V_{105\%}$ among FIF-IMRT-EB, FIF-IMRT-IB, and IMRT-IB.




Figure 2. Transverse dose-distribution curves of target-volume coverage and doses to organs at risk for the six techniques in a representative patient.

Table 3. Comparison of planning target volume, organs at risk, and cost of treatment among the six radiotherapy techniques.

Dosimetric parameters	3DCRT	IMRT + EB	FIF-IMRT+EB	FIF-IMRT +IB	IMRT+IB	VMAT+VB
PTV-WBI						
CI	0.16 ± 1.64 ^A	0.14 ± 1.45 ^{B,a}	0.16 ± 1.51 ^{B,c}	0.17 ± 1.48 ^{B,e}	0.18 ± 1.48 ^{B,g}	0.07 ± 1.17 ^{B,b,d,f,h}
HI	0.03 ± 0.28 ^A	0.06 ± 0.30 ^a	0.02 ± 0.28 ^c	0.01 ± 0.27 ^e	0.05 ± 0.29 ^g	0.10 ± 0.37 ^{B,b,d,f,h}
Dmean (cGy)	48.1 ± 4290.0 ^A	55.6 ± 4228.3 ^{B,a}	43.6 ± 4210.0 ^{B,c}	50.3 ± 4270.1 ^{B,d}	62.2 ± 4283.0 ^{B,d}	43.9 ± 4278.4 ^{B,d}
V ₉₅ (%)	0.9 ± 98.9 ^A	1.2 ± 97.9 ^a	0.8 ± 98.3 ^c	0.83 ± 98.6 ^e	1.2 ± 98.3 ^g	2.6 ± 96.0 ^{B,b,d,f,h}
V ₁₀₅ (%)	10.2 ± 50.4 ^A	10.2 ± 33.8 ^{B,a}	6.7 ± 25.6 ^{B,b,c}	9.0 ± 38.5 ^{B,d,e}	9.7 ± 44.8 ^{B,b,d,f,g}	6.8 ± 55.6 ^{B,d,f,h}
PTV-boost						
CI	0.23 ± 1.62 ^A	0.21 ± 1.42 ^{B,a}	0.23 ± 1.40 ^{B,c}	0.33 ± 1.85 ^{B,b,d,e}	0.37 ± 1.97 ^{B,b,d,g}	0.32 ± 1.44 ^{f,h}
HI	0.02 ± 0.10 ^A	0.02 ± 0.10 ^a	0.20 ± 0.09 ^c	0.01 ± 0.07 ^{B,b,e}	0.03 ± 0.08 ^{B,g}	0.05 ± 0.16 ^{B,b,d,f,h}
Dmean (cGy)	63.6 ± 4936.3 ^A	69.4 ± 4890.2 ^B	47.4 ± 4875.7 ^{B,a}	35.9 ± 4886.3 ^B	54.4 ± 4901.0 ^B	55.9 ± 4919.5 ^B
V ₉₅ (%)	1.4 ± 99.3 ^A	2.2 ± 98.2 ^a	2.1 ± 98.2 ^c	1.0 ± 99.5 ^{d,e}	1.31 ± 99.4 ^g	2.9 ± 96.4 ^{B,b,d,h}
V ₁₀₅ (%)	17.2 ± 23.5 ^A	18.0 ± 13.0 ^{B,a}	9.8 ± 4.8 ^{B,c}	0.6 ± 0.2 ^{B,b,e}	14.4 ± 7.7 ^{B,g}	13.2 ± 28.4 ^{B,d,f,h}
Heart						
Dmean (cGy)	69.5 ± 216.1 ^A	55.7 ± 206.0 ^a	62.3 ± 217.1 ^c	67.3 ± 248.4 ^e	60.0 ± 237.9 ^g	17.7 ± 376.9 ^{B,b,d,f,h}
V _{8Gy} (%)	1.9 ± 4.3 ^A	1.7 ± 4.4 ^a	1.8 ± 4.6 ^c	1.9 ± 4.5 ^e	1.7 ± 4.4 ^g	1.5 ± 6.7 ^{B,b,d,f,h}
V _{16Gy} (%)	1.6 ± 3.1 ^A	1.3 ± 3.0 ^a	1.6 ± 3.3 ^a	1.6 ± 3.3 ^c	1.3 ± 3.0 ^a	0.9 ± 2.2 ^{B,b,d}
V _{20Gy} (%)	1.5 ± 2.8 ^A	1.2 ± 2.6 ^a	1.5 ± 3.0 ^c	1.5 ± 3.0 ^e	1.2 ± 2.6 ^g	0.6 ± 1.3 ^{B,b,d,f,h}
CA						
Dmean (cGy)	570.4 ± 1208.3	470.0 ± 1146.1	514.9 ± 1211.8	515.7 ± 1232.3	468.9 ± 1167.1	180.3 ± 976.7
V _{8Gy} (%)	18.0 ± 35.8	15.7 ± 36.2	16.6 ± 36.8	17.1 ± 36.7	17.4 ± 34.2	11.1 ± 44.0
V _{16Gy} (%)	16.0 ± 27.3 ^A	13.5 ± 26.2	15.0 ± 28.4 ^a	15.1 ± 28.4 ^c	13.5 ± 26.3	8.4 ± 17.7 ^{B,b,d}
V _{20Gy} (%)	15.3 ± 25.0 ^A	12.5 ± 22.8 ^a	14.4 ± 25.7 ^c	14.4 ± 25.8 ^e	12.5 ± 22.9 ^g	6.5 ± 10.7 ^{B,b,d,f,h}
Ipsilateral lung						
Dmean (cGy)	169.7 ± 590.9 ^A	152.1 ± 544.6 ^a	160.9 ± 577.1 ^c	158.3 ± 606.4 ^e	148.7 ± 573.4 ^g	72.7 ± 786.8 ^{B,b,d,f,h}
V _{4Gy} (%)	7.0 ± 23.4 ^A	6.6 ± 22.6 ^a	6.6 ± 23.3 ^c	6.7 ± 25.0 ^e	6.7 ± 24.3 ^g	3.0 ± 48.0 ^{B,b,d,f,h}
V _{8Gy} (%)	4.8 ± 16.1 ^A	4.5 ± 15.5 ^a	4.7 ± 16.1 ^c	4.7 ± 16.3 ^e	4.5 ± 15.6 ^g	2.8 ± 30.1 ^{B,b,d,f,h}
V _{16Gy} (%)	3.8 ± 12.3 ^A	3.6 ± 11.5 ^a	3.8 ± 12.3 ^c	3.8 ± 12.4 ^e	3.5 ± 11.5 ^g	1.2 ± 16.1 ^{B,b,d,f,h}
Contralateral lung						
Dmean (cGy)	3.2 ± 6.6 ^A	1.4 ± 5.2 ^a	1.3 ± 5.0 ^c	6.2 ± 21.2 ^{B,b,d,e}	6.3 ± 21.3 ^{B,b,d,g}	34.4 ± 168.4 ^{B,b,d,f,h}
V _{4Gy} (%)	0.1 ± 0.1 ^A	0 ± 0 ^a	0 ± 0 ^c	0 ± 0 ^e	0 ± 0 ^g	3.8 ± 5.7 ^{B,b,d,f,h}
Contralateral breast						
Dmax (cGy)	20.1 ± 94.9 ^A	13.0 ± 75.5 ^{B,a}	13.5 ± 92.5 ^c	32.2 ± 136.1 ^{B,b,d,e}	32.4 ± 120.3 ^{B,b,d,f,g}	39.7 ± 350.7 ^{B,b,d,h}
V _{1.44Gy} (%)	0 ± 0 ^A	0 ± 0 ^a	0 ± 0 ^c	0.3 ± 0.1 ^e	0.2 ± 0.1 ^g	13.4 ± 19.1 ^{B,b,d,f,h}
Cost *	0.0 ± 11731.0 ^A	0.0 ± 21241.0 ^{B,a}	6171.6 ± 13621.0 ^{B,b,c}	0.0 ± 39841.0 ^{B,b,d,e}	0.0 ± 39841.0 ^{B,b,d,g}	0.0 ± 27211.0 ^{B,b,d,f,h}
MU	15.4 ± 389.2 ^A	54.4 ± 516.2 ^{B,a}	11.0 ± 372.0 ^{B,c}	33.9 ± 502.70 ^{B,e}	72.8 ± 644.5 ^{B,f,g}	51.0 ± 799.6 ^{B,d,h}

3DCRT, three-dimensional conformal radiation therapy; CA, coronary artery; CI, conformity index; EB, electron boost; FIF, field-in-field; HI, homogeneity index; IB, IMRT boost; IMRT, intensity-modulated radiation therapy; PTV, planning target volume; VB, VMAT boost; VMAT, volumetric-modulated arc therapy; WBI, whole-breast irradiation.

*The exchange rate was 1 US dollar to 6.8 Renminbi (RMB) on 12 June 2017.

ASignificantly different from B ($p < 0.05$); asignificantly different from b ($p < 0.05$); csignificantly different from d ($p < 0.05$), esignificantly different from f ($p < 0.05$); gsignificantly different from h ($p < 0.05$). Otherwise, no significant differences were present between any two variables ($p > 0.05$).

Doses to OAR

The Dmean and V_{8Gy} of the heart were significantly higher and the V_{20Gy} was significantly lower for VMAT-VB than for the other five plans ($p < 0.05$). There were no significant differences among the non-VMAT plans in terms of Dmean, V_{8Gy}, V_{16Gy}, and V_{20Gy} of the heart ($p > 0.05$; table 3). For the coronary

artery, the V_{16Gy} was significantly lower for VMAT-VB than for the remaining five plans ($p < 0.05$), but there were no significant differences in Dmean and V_{8Gy} among the six plans ($p > 0.05$; table 3).

Our analysis of the dose to the ipsilateral lung showed that VMAT-VB had the highest Dmean, V_{4Gy}, V_{8Gy}, and V_{16Gy} ($p < 0.05$) among all the

plans. The Dmean and V_{4Gy} of the contralateral lung were also higher for VMAT-VB than for the remaining five plans ($p < 0.05$). The 3DCRT-EB plan yielded a lower Dmean for the contralateral lung than did the plans with IMRT boosts ($p < 0.05$; table 3).

Among the six plans, VMAT-VB had the highest maximum dose (Dmax) and $V_{1.44Gy}$ for the contralateral breast ($p < 0.05$). Plans with the SIB delivered via an EB had a lower Dmax for the contralateral breast than did plans that used 3DCRT or an IMRT boost ($p < 0.05$;

table 3).

Cost-benefit analysis and the ranking of the six techniques

The 3DCRT plan was associated with the lowest cost, followed by the FIF-IMRT-EB; plans with an IMRT boost had the highest costs ($p < 0.05$; table 4). Of the six plans, the FIF-IMRT-EB was the most cost-effective technique. Plans with SIBs administered via IMRT or VMAT scored the lowest on the cost-benefit analysis.

Table 3. Comparison of planning target volume, organs at risk, and cost of treatment among the six radiotherapy techniques.

Dosimetric parameters	3DCRT	IMRT +EB	FIF-IMRT+ EB	FIF-IMRT + IB	IMRT+IB	VMAT+VB
TV						
PTV-WBI CI	1	4	2	2	5	6
PTV-WBI HI	1	1	1	1	1	6
V_{95} (%)	3	2	3	3	3	1
V_{48Gy} -breast PTVE	2	2	2	1	1	2
$V_{43.2Gy}$ -breast PTVE	4	5	5	2	2	1
LUMP PTVE CI	3	5	5	1	1	4
LUMP PTVE HI	2	2	2	1	2	6
LUMP PTVE V_{95} (%)	5	2	2	5	2	1
$V_{52.8Gy}$ -LUMP PTVE	2	2	2	2	2	1
Dmax-LUMP PTVE	2	2	5	5	2	1
Total	25	27	29	23	21	29
OAR						
Heart Dmean (cGy)	2	2	2	2	2	1
Heart V_{8Gy} (%)	2	2	2	2	2	1
Heart V_{20Gy} (%)	2	1	1	1	1	2
Ipsilateral lung V_{4Gy} (%)	1	2	2	2	2	1
Ipsilateral lung V_{8Gy} (%)	2	2	2	2	2	1
Ipsilateral lung V_{16Gy} (%)	2	2	2	2	2	1
Contralateral lung V_{4Gy} (%)	2	2	2	2	2	1
Contralateral breast Dmax (cGy)	2	4	4	2	2	1
Thyroid $V_{1.44Gy}$ (%)	6	2	2	2	2	1
Total OAR	21	19	19	17	17	10
Cost	6	4	5	1	1	3
MU	5	2	6	2	2	1
Overall total	57	52	59	43	41	43

3DCRT, three-dimensional conformal radiation therapy; CI, conformity index; Dmax, maximum dose; Dmean, mean dose; EB, electron boost; FIF, field-in-field; HI, homogeneity index; IB, IMRT boost; IMRT, intensity-modulated radiation therapy; MU, monitor unit; OAR, organs at risk; PTVE, planning target volume evaluation; TV, target volume; VB, VMAT boost; VMAT, volumetric-modulated arc therapy; WBI, whole-breast irradiation.

DISCUSSION

Currently, there is no standard to guide the use of SIB during hypofractionated WBI after BCS. Therefore, an optimal irradiation technique based on contemporary treatment modes should be explored. In this study, we compared the advantages and disadvantages of six techniques for hypofractionated WBI with SIB by analyzing the target-volume coverage, doses to OAR, and cost-effectiveness of each plan.

A randomized trial has found that photon-beam irradiation is associated with adverse *cosmetic outcomes* after tumor bed boost with conventional dose fractionation⁽¹⁴⁾, which may be attributable to the dosimetric characteristics of the photon beams and the use of *outdated radiotherapy techniques*. Recent studies have found that IMRT provides better whole-breast dose uniformity than 3DCRT^(22, 23). The CI and HI of target-volume coverage are important factors to evaluate the superiority of radiotherapy techniques may also be critical factors affecting cosmetic outcomes in breast cancer patients. A recent study⁽²⁴⁾ of tumor bed boost after WBI showed that a better CI could be obtained by using the arc technique. The study also determined that the V95% of two-field photon-beam boost plans was significantly better than that of plans with the EB technique (94.4% vs. 79.9%); however, the CI was worse (39 vs. 47)⁽²⁴⁾. In contrast, Park et al. found that a photon boost was associated with better HI and CI values than an EB⁽²⁵⁾. The present study showed that VMAT-VB had better CI and HI for WBI, while SIBs delivered using EBs had similar CIs as those of VMAT boosts. In addition, the HI was better with the EB than with the VMAT boost.

EB is a widely used technique to deliver tumor bed boost in breast cancer due to its dosimetric characteristics. However, an EB to a deep tumor bed may increase the risk of overdose to OAR. The six irradiation techniques in our study all met the requirements of target-volume coverage and dose to OAR. Our study showed that in Chinese female patients with relatively small breasts, an EB could achieve relatively satisfactory target-volume

coverage that was similar to those of more precise techniques. Moreover, there was no significant increase in irradiation dose to OAR, including the heart and lungs.

China is a developing country, but the incidence of breast cancer in China is increasing rapidly⁽²⁶⁾. Patients with breast cancer may have to undergo surgery, chemotherapy, and even targeted therapy and subsequent adjuvant radiotherapy, which poses a heavy economic burden that significantly affects the quality of life of the patients and their prognosis⁽²⁷⁾. At SYSUCC, the cost of FIF-IMRT-EB treatment is only 20,000 Renminbi (RMB), which is more than that of 3DCRT but significantly lower than that of IMRT boosts or the VMAT technique. Moreover, our scoring model showed that FIF-IMRT-EB had the best performance. Therefore, we suggest that FIF-IMRT-EB is suitable for patients with relatively small breasts who have undergone BCS. In addition, precise radiotherapy techniques such as IMRT and VMAT tend to be influenced by respiration. Studies have found that respiration significantly affects the dose to the target volume and OAR⁽²⁸⁻³¹⁾. Although the active breathing-control technique may reduce the impact of respiration, it increases the economic burden to the patients and decreases their quality of life.

Long-term follow-up studies have found that among breast cancer patients who received radiotherapy, the mortality rate due to ischemic heart disease and lung cancer increased significantly⁽³²⁻³⁴⁾. Therefore, the survival advantage after radiotherapy was probably offset by the increased risk of cardiovascular disease and lung cancer in early series. Long-term clinical studies in the era of modern radiotherapy have not found that low-dose hypofractionated radiotherapy increases the incidence of cardiac deaths⁽³⁵⁾. New techniques, including VMAT and IMRT boosts, can expose nearby OAR to low-dose irradiation and thus further increase radiation injury^(36, 37). However, dosimetry studies have found that tangential-field IMRT, multi-directional IMRT, and VMAT can significantly decrease the risk of lung cancer⁽³⁸⁾. It should be noted that high-dose irradiation to the lung could increase

the probability of radiation-induced lung cancer⁽³⁹⁾. In our study, the Dmean to the ipsilateral lung was less than 10 Gy for each irradiation plan, but the irradiation doses to both the lungs were higher for VMAT-VB than for the other techniques. Although there have been few studies about the long-term outcomes of patients who undergo VMAT⁽¹⁵⁾, our results showed that VMAT may not be an optimal technique in breast cancer patients.

CONCLUSION

Our results suggest that relevant parameters such as target-volume coverage, dose to OAR, and cost should be considered comprehensively when selecting a technique for hypofractionated WBI with SIB. FIF-IMRT-EB may be the optimal radiation technique for breast cancer patients who will undergo hypofractionated WBI with SIB after BCS.

DISCLOSURES

The authors have no conflicts of interest to disclose.

ACKNOWLEDGMENTS

This work was supported by grants from the Sci-Tech Office of Guangdong Province [2013B021800157 and 2013B021800458]; and the Youth Foundation of Fujian Provincial Health and Family Planning Commission [2014-2-63].

Conflicts of interest: Declared none.

REFERENCES

1. Litière S, Werutsky G, Fentiman IS, et al. (2012) Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomized trial. *Lancet Oncol*, **13**: 412–419.
2. The Japanese Breast Cancer Society (2005) Results of questionnaires concerning breast cancer surgery in Japan 1980–2003. *Breast Cancer*, **12**: 1–2.
3. Lazovich D, Solomon CC, Thomas DB, Moe RE, White E (1999) Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. *Cancer*, **86**: 628–37.
4. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. (2002) Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. *J Natl Cancer Inst*, **94**: 1143–50.
5. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. (2010) Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med*, **362**: 513–20.
6. START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. *Lancet Oncol*, **9**: 331–41.
7. START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. *Lancet*, **371**: 1098–107.
8. Yarnold J, Bentzen SM, Coles C, Haviland J (2011) Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. *Int J Radiat Oncol Biol Phys*, **79**:1–9.
9. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. *J Clin Oncol*, **25**: 3259–65.
10. Coles C and Yarnold J (2006) IMPORT trials management group The IMPORT trials are launched (September 2006). *Clin Oncol (R Coll Radiol)*, **18**: 587–90.
11. Higher-dose radiation therapy or standard radiation therapy in treating patients with early-stage breast cancer that was removed by surgery. Available at: <http://clinicaltrials.gov/ct2/show/NCT01349322>.
12. Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, et al. (2012) Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. *Radiat Oncol*, **7**: 80.
13. Radiation therapy oncology group. RTOG 1005 Protocol Information, 2014 [2014-7-31]. <http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1005>
14. Immink JM, Putter H, Bartelink H, Cardoso JS, Cardoso MJ, van der Hulst-Vijgen MH, et al. (2012) Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial. *Ann Oncol*, **23**: 2591–8.
15. Scorsetti M, Alongi F, Fogliata A, Pentimalli S, Navarria P, Lobefalo F, et al. (2012) Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modu-

- lated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. *Radiat Oncol*, **7**: 145.
16. Mukesh MB, Barnett GC, Wilkinson JS, Moody AM, Wilson C, Dorling L, et al. (2013) Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. *J Clin Oncol*, **31**: 4488-95.
17. He Z, Wu S, Zhou J, Li F, Sun J, Lin Q, et al. (2014) Accelerated partial breast irradiation with intensity-modulated radiotherapy is feasible for Chinese breast cancer patients. *J Breast Cancer*, **17**: 256-64.
18. ICRU (2010) Report 83. Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). International Commission on Radiation Units and Measurements, Bethesda.
19. Wu S, Lai Y, He Z, Zhou Y, Chen S, Dai M, et al. (2015) Dosimetric comparison of the simultaneous integrated boost in whole-breast irradiation after breast-conserving surgery: IMRT, IMRT plus an electron boost and VMAT. *PLoS One*, **10**: e0120811.
20. Hong L, Hunt M, Chui C, Spirou S, Forster K, Lee H, et al. (1999) Intensity-modulated tangential beam irradiation of the intact breast. *Int J Radiat Oncol Biol Phys*, **44**: 1155-64.
21. Gurjar OP and Mishra SP (2013) Dosimetric analysis of intensity modulated radiotherapy plans having one or more pairs of parallel opposed beams among the set of beams in some special cases. *Radiat Prot Environ*, **36**:138-42.
22. Chen GP, Liu F, White J, Vicini FA, Freedman GM, Arthur DW, et al. (2014) A planning comparison of 7 irradiation options allowed in RTOG 1005 for early-stage breast cancer. *Med Dosim*, **40**: 21-5.
23. Yavas G, Yavas C, Acar H (2012) Dosimetric comparison of whole breast radiotherapy using field in field and conformal radiotherapy techniques in early stage breast cancer. *Iran JRR*, **10**:131-8.
24. Van Parijs H, Reynders T, Heuninckx K, Verellen D, Storme G, De Ridder M (2014) Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery. *Radiat Oncol*, **9**: 36.
25. Park SH and Kim JC (2013) Comparison of electron and x-ray beams for tumor bed boost irradiation in breast-conserving treatment. *J Breast Cancer*, **16**: 300-7.
26. Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, et al. (2011) A nation-wide multicenter 10-year (1999e 2008) retrospective clinical epidemiological study of female breast cancer in China. *BMC Cancer*, **11**:364.
27. De Aguiar SS, Bergmann A, Mattos IE (2014) Quality of life as a predictor of overall survival after breast cancer treatment. *Qual Life Res*, **23**: 627-37.
28. Reardon KA, Read PW, Morris MM, Reardon MA, Geesey C, Wijesooriya K (2013) A comparative analysis of 3D conformal deep inspiratory-breath hold and free-breathing intensity-modulated radiation therapy for left-sided breast cancer. *Med Dosim*, **38**: 190-5.
29. Sung K, Lee KC, Lee SH, Ahn SH, Lee SH, Choi J (2014) Cardiac dose reduction with breathing adapted radiotherapy using self-respiration monitoring system for left-sided breast cancer. *Radiat Oncol J*, **32**: 84-94.
30. Chi F, Wu SG, Zhou J, Li FY, Sun JY, Lin Q, et al. (2015) Dosimetric comparison of moderate deep inspiration breath-hold and free-breathing intensity-modulated radiotherapy for left-sided breast cancer. *Cancer Radiother*, **19**: 180-6.
31. Chang-li R, Yu-xin C, Lu-zhou W, WU-bing, Qi-bin S (2015) The influence of respiratory motion on dose distribution of 3D-CRT and IMRT- A simulation study. *Int J Radiat Res*, **13**: 39-43.
32. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*, **368**: 987-98.
33. McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM, et al. (2011) Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. *Radiother Oncol*, **100**: 167-75.
34. Henson KE, McGale P, Taylor C, Darby SC (2013) Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. *Br J Cancer*, **108**: 179-82.
35. Chan EK, Woods R, Virani S, Speers C, Wai ES, Nichol A, et al. (2014) Long-term mortality from cardiac causes after adjuvant hypofractionated vs. conventional radiotherapy for localized left-sided breast cancer. *Radiother Oncol*, **114**: 73-8.
36. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst*, **99**: 365-75.
37. Schultz-Hector S and Trott KR (2007) Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? *Int J Radiat Oncol Biol Phys*, **67**: 10-8.
38. Abo-Madyan Y, Aziz MH, Aly MM, Schneider F, Sperk E, Clausen S, et al. (2014) Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer. *Radiother Oncol*, **110**: 471-6.
39. Grantzau T, Thomsen MS, Væth M, Overgaard J (2014) Risk of second primary lung cancer in women after radiotherapy for breast cancer. *Radiother Oncol*, **111**: 366-73.